Kentaro Takeda

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 19

Top Venues

Pharmaceutical statistics

Statistical methods in medical research

Biometrical journal. Biometrische Zeitschrift

Journal of biopharmaceutical statistics

Yokohama City University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Yokohama City University Apr 01 2012 - Mar 31 2016

Japan

PHD

Osaka University Apr 01 2000 - Mar 31 2002

Japan

MSC

Osaka University Apr 01 1996 - Mar 31 2000

Japan

BSC

Publications

Tomoyuki Kakizume, Kentaro Takeda, Masataka Taguri, Satoshi Morita
BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations. Statistical methods in medical research 33 (4) (2024)
J C Poythress, Jin Hyung Lee, Kentaro Takeda, Jun Liu
Bayesian Methods for Quality Tolerance Limit (QTL) Monitoring. Pharmaceutical statistics (2024)
Kentaro Takeda, Atsuki Hashimoto, Shufang Liu, Alan Rong
A basket trial design based on constrained hierarchical Bayesian model for latent subgroups. Journal of biopharmaceutical statistics (2024)
Qing Xia, Kentaro Takeda, Yusuke Yamaguchi, Jun Zhang
A generalized Bayesian optimal interval design for dose optimization in immunotherapy. Pharmaceutical statistics (2024)
Tomoyuki Kakizume, Kentaro Takeda, Masataka Taguri, Satoshi Morita
BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations. Statistical methods in medical research (2024)
Tomoyuki Kakizume, Kentaro Takeda, Masataka Taguri, Satoshi Morita
BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations. Statistical methods in medical research 33 (4) (2024)
Qing Xia, Kentaro Takeda, Yusuke Yamaguchi, Jun Zhang
A generalized Bayesian optimal interval design for dose optimization in immunotherapy. Pharmaceutical statistics 23 (4) (2024)
Kentaro Takeda, Jing Zhu, Ran Li, Yusuke Yamaguchi
A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology. Pharmaceutical statistics (2023)
Kentaro Takeda, Yusuke Yamaguchi, Masataka Taguri, Satoshi Morita
TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes. Biometrical journal. Biometrische Zeitschrift (2023)
Yusuke Yamaguchi, Kentaro Takeda, Satoshi Yoshida, Kazushi Maruo
Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study. Journal of biopharmaceutical statistics (2023)
Yunqi Zhao, Rachael Liu, Kentaro Takeda
Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET. Pharmaceutical statistics (2022)
Kentaro Takeda, Satoshi Morita, Masataka Taguri
gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials. Biometrical journal. Biometrische Zeitschrift 64 (7) (2022)
Shufang Liu, Kentaro Takeda, Alan Rong
An adaptive biomarker basket design in phase II oncology trials. Pharmaceutical statistics (2022)
Kentaro Takeda, Shufang Liu, Alan Rong
Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers. Statistics in medicine (2021)
Kentaro Takeda, Qing Xia, Shufang Liu, Alan Rong
TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades. Pharmaceutical statistics (2021)
Kentaro Takeda, Satoshi Morita, Masataka Taguri
TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes. Pharmaceutical statistics 19 (3) (2019)
Kentaro Takeda, Masataka Taguri, Satoshi Morita
BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes. Pharmaceutical statistics 17 (4) (2018)
Kentaro Takeda, Satoshi Morita
Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial. Pharmaceutical statistics 17 (4) (2018)
Kentaro Takeda, Kanji Komatsu, Satoshi Morita
Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology. Pharmaceutical statistics 17 (6) (2018)

Kentaro Takeda.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Kentaro Takeda